Dare Bioscience Inc (DARE)is dedicated to the development of innovative products in women’s health. The company stock was up 31.36% to $3.1 in the after-market session.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
What they do…
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
The company’s mission is to identify, develop and market a diverse portfolio of differentiated therapies for women, mainly in the areas of contraception, vaginal health, sexual health, and fertility.
Read More
- Top 3 Cloud Computing Stocks to Watch For in 2021
- 3 Best Work-From-Home Stocks for Long-term Investment
While the latest rally in the Corporate Universe stock is extremely impressive, nothing material related to the company’s business was announced that could have prompted such a move. Thus, it could be necessary to see something that took place in a recent couple of months.
Recent Developments
January 05, 2021, Daré Bioscience Inc., a pioneer in research in women’s health (NASDAQ: DARE), announced that its Founder and Chief Executive Officer, Sabrina Martucci Johnson, is engaging in a fireside chat at the H.C. Wainwright Interactive Conference BIOCONNECT 2021 on 11-14 January 2021.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
December 7, 2020, DARE-BVFREE phase 3 randomised, double aveugled, placebo-controlled clinical trial assessment of DARE-BV1 among 307 women afflicted with bacterial vaginosis, a severe disease projected to affect approximately 21 million females in the United States, was disclosed by Daré Bioscience, Inc. (NASDAQ: DARE). DARE-BV1 is a research thermosetting bioadhesive hydrogel containing clindamycin phosphate 2 percent and is intended to be used as an easy, one-time vaginal bacterial vaginosis treatment. The trial found its primary outcome that a single DARE-BV1 administration was superior to placebo as the key clinical tool for bacterial vaginosis diagnosed women.
